Cleary Gottlieb acted as international counsel for CFR Pharmaceuticals S.A. and its principal shareholder in the company’s $370 million debut global equity offering, which was comprised of an initial public offering by special auction on the Santiago Stock Exchange and a Rule 144A/Reg S offering in the United States and outside Chile.
The initial public offering of shares, including in the form of ADSs, closed on May 9, 2011.
CFR Pharmaceuticals S.A. is a leading Latin American pharmaceutical company with operations in 15 countries across the region and certain other emerging markets. Its business model is focused on the development, manufacture and commercialization of off-patent and locally unpatented branded specialty pharmaceutical products.
